Pharmacokinetics of Benapenem in Subjects With Renal Impairment
Status:
Completed
Trial end date:
2019-10-21
Target enrollment:
Participant gender:
Summary
This is an open-label, multiple center, parallel-group Study to compare the pharmacokinetics
and safety of single-dose benapenem (1.0mg) in subjects with mild or moderate Renal
Impairment(RI) and healthy subjects. Subjects were enrolled with defined degrees of RI based
on eGFR(estimated Glomerular Filtration Rate) calculated by MDRD (Modification of Diet in
Renal Disease)formular as follows: nomal renal function(≥90ml/min/1.73m2 ; N=6); mild RI
(60-89mL/min/1.73 m2 ; N=6), moderate RI (30-59 mL/min/1.73m2 ; N=6)